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ABSTRACT
OBJECTIVE: To evaluate the impact of nonnutritive sugar substitutes on glycemic control in
patients with diabetes.
DATA SOURCES: A comprehensive review of the literature was conducted in PubMed (1966 March 2012) and Scopus. A combination of MeSH terms and keywords were used including:
acesulfame, aspartame, diabetes, neotame, rebiana, saccharin, stevia, and sucralose.
STUDY SELECTION AND DATA EXTRACTION: Clinical studies evaluating the impact of
nonnutritive sweeteners on measures of diabetic control, including but not limited to, blood
glucose levels, postprandial blood glucose, and hemoglobin A1C were selected for review.
Searches were limited to only nonnutritive sweeteners available in the United States.
DATA SYNTHESIS: Nine clinical trials were found that evaluated nonnutritive sweeteners in a
total of 490 patients with diabetes. Doses of sweeteners varied in the studies from doses below
acceptable daily intake levels for 3 consecutive days to daily dosing for up to 18 weeks and up to
3.5 times the acceptable daily intake levels. No significant differences in overall effects on
glycemic control and insulin response were found.
CONCLUSIONS: Nonnutritive sweeteners do not appear to affect glycemic control in patients
with diabetes. Patients should be counseled to maintain an appropriate energy balance in their
diet, with or without the use of nonnutritive sweeteners.
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BACKGROUND
More than 25 million people in the U.S. are affected by diabetes. The number of
Americans diagnosed with diabetes has more than tripled in the last 30 years. In 2010, more than
1 in 4 U.S. residents over the age of 65 had a diagnosis of diabetes.1 Diabetic complications
result in significant morbidity, mortality, and costs to the healthcare system. Avoiding increased
caloric intake is important, and many individuals elect to use sugar substitutes in food and
beverages as a way to enhance taste without added calories and carbohydrates.
Nonnutritive sweeteners are agents that have little to no calories, and thus provide
negligible energy. These agents are alternatives to nutritive sweeteners such as refined sugar,
high fructose corn syrup, fructose, and dextrose, among others. Nonnutritive sugar substitutes are
at least 100 times sweeter than regular sugar which is why such a small amount is needed for
flavor.2 Close to 200 million people in the U.S. consume these sweeteners with half that many
consuming them daily.3
It has been hypothesized that by adding nonnutritive sweeteners in place of calorie
producing sweeteners in foods, consumers would end up consuming more overall by eating or
drinking additional food and drink to replace the calories that were avoided initially.4 The
potential benefit to using nonnutritive sweeteners in patients with diabetes is the advantage of
still being able to consume sweet foods and beverages, but not increasing calories. This would,
however, be disadvantageous to use these products if patients were replacing them with
increased carbohydrate content to make up for missed calories.
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Seven sugar substitutes are recognized as food additives Generally Recognized As Safe
(GRAS) by Food and Drug Administration (FDA): acesulfame-K (Sunett®, Sweet One®),
aspartame (NutraSweet®, Equal®), luo han guo extract (monk fruit extract), saccharin (Sweet ‘N
Low®, Sugar Twin®), sucralose (Splenda®), Stevia (also known as Truvia®, Rebaudioside A,
Reb-A, or rebiana), and neotame.5-7 Additionally, the American Diabetes Association (ADA) and
the American Dietetic Association (ADietA) have supported use of these agents when consumed
within acceptable daily intake levels as defined by the FDA (Grade A recommendation).2,8,9
Treatment strategies to prevent diabetic complications are aimed at controlling blood
glucose (BG), blood pressure (BP) and lipids in conjunction with other preventative care. Sugar
substitutes are often used by patients as a means to avoid excess calories and carbohydrates;
however the potential impact on measures of glucose control is important. The objective of this
article is to review the literature to evaluate the effects of nonnutritive sugar substitutes on
measures of glucose control in patients with diabetes.
LITERATURE REVIEW
Pubmed (1966 – May 2012) and Scopus (1949 – May 2012) were searched using the
each of the search terms acesulfame, aspartame, luo han guo, monk fruit, neotame, rebiana,
saccharin, stevia, and sucralose with the search term diabetes. All English language clinical
studies that evaluated the impact of any of these nonnutritive sweeteners available in the U.S. on
measures of diabetic control, including but not limited to, blood glucose levels, postprandial
blood glucose and hemoglobin A1C were selected for review. References of the identified
studies as well as position statements on nonnutritive sweeteners from the Academy of Nutrition
and Dietetics, American Diabetes Association and the American Dietetic Association were
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reviewed for additional studies.2, 5, 7- 9 Studies evaluating effects of a single dose of nonnutritive
sweeteners were excluded. A total of nine clinical trials were identified and evaluated (5aspartame, 2-stevia, 1-saccharin, and 1-sucralose). No studies were found that met the criteria
with acesulfame, luo han guo extract or neotame.
Aspartame
The majority of studies assessing effects of nonnutritive sweeteners on glycemic control
have utilized aspartame. Five studies were found including three that compared aspartame intake
to a control. Altogether they evaluated effects of 48 to 1800 mg of aspartame in a total of 169
patients with diabetes and 6 healthy subjects with daily use for three days to eighteen weeks.10-14
Okuno and colleagues investigated the effects of 125 mg aspartame consumed daily for 2
weeks on blood glucose, insulin, and glucagon secretion compared to the week before and after
the aspartame diet weeks. Nine participants with diabetes received a “jellycake” with 125 mg
aspartame daily for 2 weeks. Following administration, there were no significant differences in
the 50 gram glucose tolerance test or postprandial blood glucose. Additionally, no significant
differences were found with fasting blood cholesterol, HDL-cholesterol, or triglycerides.10
Stern et al. evaluated the effects of 1800 mg of aspartame or placebo given daily in
capsules to patients with type 2 diabetes (n=69) for 90 days in a randomized, controlled trial. At
the end of the treatment period, there were no significant differences in fasting glucose levels or
in serum phenylalanine, tyrosine, or weight after aspartame administration. The most common
adverse effect reported was mild gastrointestinal complaints in both treatment groups.11
Colagiuri and colleagues evaluated the effects of adding 4500 mg sucrose or 162 mg
aspartame daily to the usual diet of well-controlled group of patients with type 2 diabetes (n=9)
for 6 weeks before crossing over to the other group for another 6 weeks. Patients added
6

unlabeled packets of the assigned sweetener to their food or beverages. At the end of each 6
week treatment period, there were no significant changes in fasting and post-meal glucose
concentrations, overall glucose control, body weight, total cholesterol, HDL cholesterol, or
triglycerides between sucrose and aspartame.12
Kullessa et al. evaluated the effects of aspartame 30 mg capsules or placebo on glycemic
effects in patients diagnosed with either type 1 or type 2 diabetes (n=62). Patients were
randomized to receive aspartame or placebo and were instructed to take 3 capsules with each
meal, for a total of 9 capsules daily, for 18 weeks with follow-up visits approximately every 3
weeks. At the conclusion of the study, there were no significant changes in plasma glucose or
A1C levels in either group. The patients also experienced similar adverse reactions, including
constipation, itching, gastroenteritis, and diarrhea, in both the placebo and aspartame group.13
Shigeta et al. evaluated the effects on fasting plasma glucose of diets sweetened with 24
to 48 mg of aspartame for three days in 20 patients with type 2 diabetes and in 6 healthy patients.
No significant differences were found in plasma glucose levels in either group when compared to
baseline.14
Saccharin
One randomized, controlled, cross-over trial has been conducted evaluating the effects of
saccharin on glucose and insulin levels in a total of seventeen patients with type 2 diabetes.15
Cooper and colleagues compared supplementation of a regular diet with either 28 g sucrose or 30
g of starch and saccharin (equivalent in sweetness and energy, respectively to 28 g sucrose) daily
for 6 weeks. No information was provided about what type of starch was used or any more
specifics of the saccharin dose used in the study. No statistically significant effects were found
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with the saccharin on plasma glucose levels, insulin and glucagon levels at any time point after
ingestion.15
Stevia
Stevia leaves are composed of multiple steviol glycosides: stevioside, rebaudiosides A
through F, steviolbioside, and dulcoside A. All of the glycosides produce a sweet taste;
however, stevioside and rebaudioside A are the most sweet and most abundant.16 Two
randomized, controlled trials have been reported evaluating the effects of steviol glycosides on
blood glucose in 152 patients with type 1 and type 2 diabetes.17-18 Barriocanal et al. evaluated
the effects of steviol glycosides on blood glucose and blood pressure in a parallel study in 16
patients with type 1 diabetes, 30 with type 2 diabetes, and 30 healthy patients. Patients were
randomized to receive either placebo or steviol glycosides 250 mg capsules three times daily for
3 months. No statistically significant differences were found between baseline and post
treatment assessments in fasting blood glucose, A1C, systolic blood pressure, or diastolic blood
pressure in the type 2 diabetes group and the healthy patient group. There were statistically
significant differences reported in the type 1 diabetes placebo group for changes in mean systolic
blood pressure (SBP) and fasting blood glucose. Mean SBP levels were 108.3 mmHg at baseline
versus 105.7 mmHg at the end of the study (p<0.05). Mean glucose levels in the placebo group
changed from baseline to end of the study from 219 to 298 mg/dl in patients with type 1 diabetes,
from 131 to 119 mg/dl (p<0.05) in patients with type 2 diabetes and from 83 to 84 mg/dl in
patients without diabetes. A1C levels changed from 8.2% to 8.3% in type 1, from 6.8% to 6.7%
in type 2 and from 5.3% to 5.4% in patients without diabetes.17
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Maki et al. conducted a multi-center, randomized, double-blind, placebo controlled, 16week trial investigating the effects of rebaudioside A on glycemic and hemodynamic effects in
122 patients with type 2 diabetes. Patients were randomized to receive either placebo or
rebaudioside A in four 250 mg capsules daily (1,000 mg daily). No statistically significant
differences were found with the primary outcome of the study, change in A1C from baseline to
week 16. A1c was 6.71% and 6.70% in the rebaudioside A and placebo groups respectively at
baseline and increased by 0.11% and 0.09% respectively (p = 0.355) at week 16. No statistically
significant differences were reported for fasting levels of glucose, insulin, C-peptide, intakes of
total energy, or percentages of energy from carbohydrates from baseline to end of the study. No
differences in hypoglycemic events were reported between the groups.18
Sucralose
One randomized, double-blind, placebo-controlled trial evaluated the effects of either
sucralose 667 mg (n = 67) or placebo (n = 69) daily on glycemic control in patients with type 2
diabetes.19 Patients participated in a 4-week placebo run in phase and then were randomized to
either placebo or sucralose provided in capsules to be taken with meals for 13 weeks.
Participants were asked to follow a diet of 14% protein, 30-36% fat and 48-55% carbohydrate
and to measure capillary blood glucose at least three times daily. No statistically significant
difference was found between the treatment groups in A1C over time. A1C levels were reported
to have decreased significantly after 2 weeks of treatment in the sucralose group; however, A1C
at this time point would not have been specific to the sucralose beginning only 2 weeks prior.
No statistically significant differences were reported in fasting plasma glucose concentrations
between the groups (between treatment difference from baseline -1.13 mg/dL, p = 0.89) or in
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fasting C-peptide (between treatment difference 150 ng/mL, p = 0.29). No adverse events were
documented related to sucralose.19
DISCUSSION
Nine clinical trials were found that evaluated nonnutritive sweeteners in a total of 490
patients with diabetes.10-15,17,18 Doses of nonnutritive sweeteners varied in the studies, but all
were below the acceptable daily intake levels in studies of aspartame and saccharin. The studies
evaluating sucralose and stevia utilized doses up to 3.5 times the acceptable daily intake levels
for a 70 kg adult (table 1).2,17-19 The studies evaluated effects of daily intake over a period of 3
days to 18 weeks. The study by Kullessa et al. evaluated the highest dose of a nonnutritive
sweetener (2.7 g/day of aspartame) for the longest time period (18 weeks).13 No significant
differences in overall effects on glycemic control and insulin response were found in any of the
multiple dose studies.
Many of the studies evaluated were randomized, cross-over studies assessing a
nonnutritive sweetener against a control. In most cases the control used was cellulose which has
been shown to have no significant impact on glycemic control.11-13,17,18,20 The study by Cooper
and colleagues added starch to the saccharin dose to be an equal amount of energy to the sucrose
in the other trial arm. The addition of the calories with the starch to equal that of sucrose would
decrease the beneficial effects that were being investigated with replacing sucrose with a
nonnutritive sweetener. It is not surprising that no changes in glucose levels were identified in
this trial. Doses of nonnutritive sweeteners in amounts similar or greater than what is usually
consumed in a packet of the nonnutritive sweetener were used. Most of the studies however,
evaluated a small number of patients and did not measure long term glycemic control and safety.
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It is understandable that doses of nonnutritive sweeteners in the study were often consumed via
capsules; however, ideally, consumption of the nonnutritive sweeteners would have been via
food products as this would be more true to normal consumption. Most studies used A1C as the
primary measure of glycemic control, which would be an inadequate marker in the studies that
were conducted over fewer than 120 days. There is a possibility that patients in the studies
consumed a healthier diet than what they would normally consume because they knew they were
enrolled in a study and would be monitored.
Mattes and Popkin reviewed the literature evaluating the effects of nonnutritive
sweeteners on appetite and food intake in humans and reported that only observational studies
have evaluated long-term use of nonnutritive sweeteners in the diet. The studies they found
produced conflicting evidence, but principally found no overall effects on the primary variable
measured, body mass index (BMI).21 Larger, randomized trials assessing chronic effects on
post-prandial blood glucose levels and A1C, dietary compliance and body weight control may be
beneficial to confirm results found in shorter term studies.

SUMMARY
Overall, it appears that nonnutritive sweeteners may be used by patients with diabetes
without affecting glycemic control. These agents have been generally recognized as safe when
consumed in amounts below the acceptable daily intake levels. Patients should be counseled to
maintain an appropriate energy balance in their diet, with or without the use of nonnutritive
sweeteners.

11

REFERENCES
1. Centers for Disease Control and Prevention. National diabetes fact sheet: national
estimates and general information on diabetes and prediabetes in the United States, 2011.
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. (accessed 2012 Jun 13).
2. Duffy VB, Anderson GH. Position of the American Dietetic Association: use of nutritive
and nonnutritive sweeteners. J Am Diet Assoc 1998;98:580-7.
3. Bloomgarden ZT. Nonnutritive sweeteners, fructose, and other aspects of diet. Diabetes
Care. 2011; 34(5):e46-51. Erratum in: Diabetes Care 2011;34:1887.
4. Rogers PJ, Blundell JE. Separating the actions of sweetness and calories: effects of
saccharin and carbohydrates on hunger and food intake in human subjects. Physiol Behav
1989;45:1093-9.
5. American Diabetes Association. Artificial sweeteners. http://www.diabetes.org/food-andfitness/food/what-can-i-eat/artificial-sweeteners/ (accessed 2012 Jun 13).
6. U.S. Food and Drug Administration. Is Stevia an ‘FDA approved’ sweetener?
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm214864.htm?utm_campaign=G
oogle2&utm_source=fdaSearch&utm_medium=website&utm_term=stevia&utm_content
=2 (accessed 2012 Jun 13).
7. Position of the Academy of Nutrition and Dietetics: Use of Nutritive and Nonnutritive
Sweeteners. J Acad Nutr Diet 2012;112:739-758.
8. Use of noncaloric sweeteners. American Diabetes Association. Diabetes Care
1987;10:526.

12

9. American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM,
Clark NG, Franz MJ, et al. Nutrition recommendations and interventions for diabetes: a
position statement of the American Diabetes Association. Diabetes Care 2008;31:S61-78.
10. Okuno G, Kawakami F, Tako H. Glucose tolerance, blood lipid, insulin and glucagon
concentration after single or continuous administration of aspartame in diabetics.
Diabetes Res Clin Pract 1986;2:23-7.
11. Stern SB, Bleicher SJ, Flores A, Gombos G, Recitas D, Shu J. Administration of
aspartame in non-insulin-dependent diabetics. J Toxicol Environ Health 1976;2:429-39.
12. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding sucrose and aspartame
to the diet of subjects with noninsulin-dependent diabetes mellitus. Am J Clin Nutr
1989;50:474-8.
13. Kullessa Nehrling J, Kobe P, McLane MP. Aspartame use by persons with diabetes.
Diabetes Care 1985;8:415-7.
14. Shigeta H, Yoshida T, Nakai M. Effects of aspartame on diabetic rats and diabetic
patients. J Nutr Sci Vitaminol 1985;31:533-40.
15. Cooper PL, Wahlqvist ML, Simpson RW. Sucrose versus saccharin as an added
sweetener in non-insulin-dependent diabetes: Short- and medium-term metabolic effects.
Diabet Med 1988;5:676-680.
16. Gardana C, Simonetti P, Canzi E, Zanchi R, Pietta P. Metabolism of stevioside and
rebaudioside A from Stevia rebaudiana extracts by human microflora. J Agric Food
Chem 2003;51:6618-6622.
17. Barriocanal LA, Palacios M, Benitez G, Benitez S, Jimenez JT, Jimenez N, et. al.
Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in

13

humans. A pilot study of repeated exposures in some normotensive and hypotensive
individuals and in Type 1 and Type 2 diabetics. Regul Toxicol Pharmacol 2008;51:37-41.
18. Maki KC, Curry LL, Reeves MS, Toth PD, McKenney JM, Farmer MV, et. al. Chronic
consumption of rebaudioside A, a steviol glycoside, in men and women with type 2
diabetes mellitus. Food Chem Toxicol 2008;46:S47-S53.
19. Grotz VL, Henry RR, Mcgill JB, Prince MJ, Shamoon H, Trout JR, et. al. Lack of effect
of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc
2003;103:1607-1612+1711.
20. Niemi MK, Keinanen-Kiukaanniemi SM, Salmela PI. Longterm effects of guar gum and
microcrystalline cellulose on glycaemic control and serum lipids in type 2 diabetes. Eur J
Clin Pharmacol 1988;34:427-9.
21. Mattes RD, Popkin BM. Nonnutritive sweetener consumption in humans: effects on
appetite and food intake and their putative mechanisms. Am J Clin Nutr 2009;89:1-14.

14

Table 1. Acceptable Daily Intake for Nonnutritive Sweeteners
Sweetener

Acceptable Daily

Dose ranges in

Intake (ADI)

studies in patients

(mg/kg/day)2,7

with diabetes9-15, 17,
18

Acesulfame K

15

Aspartame

50

Luo han guo

48 - 1800 mg

Not determined

extract
Neotame

18

Saccharin

5

135 mg –
(equivalent of 28 g
of sucrose)

Stevia

4 (steviol glycosides)

750 - 1000 mg

12 (rebaudioside A)
Sucralose

5

667 – 1000 mg

15

